MedPath

Tagged News

Nestmedic Partners with Curavit for U.S. Clinical Trial of AI-Enabled Prenatal Monitoring Device

AIFDA Approval
  • Nestmedic S.A. has selected Curavit Clinical Research to lead the U.S. clinical trial of PregnaOne, an AI-enabled remote prenatal monitoring solution designed to provide continuous insight into fetal and maternal well-being.
  • The FDA-required Non-Significant Risk study will enroll 50 expectant mothers across multiple U.S. sites over 11 months to evaluate the safety and effectiveness of home-based prenatal monitoring.
  • The trial aims to generate foundational evidence to support future regulatory approval in the U.S., with Curavit managing all aspects including IRB submissions, site selection, data management, and clinical study reporting.

Lantern Pharma Secures European Patent for AI-Developed Cancer Therapy LP-284

AIOncology
  • Lantern Pharma received European Patent Office allowance for LP-284, a next-generation acylfulvene targeting relapsed or refractory non-Hodgkin's lymphoma with patent exclusivity through early 2039.
  • The AI-developed drug candidate achieved clinical trial readiness in under three years at approximately $1.5-2.0 million cost and is currently in Phase 1 trials for aggressive NHL subtypes.
  • LP-284 has earned FDA Orphan Drug Designations for mantle cell lymphoma and high-grade B-cell lymphomas, addressing a $4 billion annual global blood cancer market.
  • The European patent strengthens Lantern's global intellectual property portfolio alongside existing patents in the US, Japan, India, and Mexico, positioning LP-284 for worldwide commercialization.

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients with Relapsed or Refractory Lymphomas and Solid Tumors

NCT06132503RecruitingPhase 1
Lantern Pharma Inc.
Posted 1/3/2023

MVP Health Care Partners with Renalytix to Expand Access to AI-Powered Kidney Disease Testing

AIPrecision MedicineFDA Approval
  • MVP Health Care and Renalytix announced a partnership to expand access to the FDA-approved kidneyintelX.dkd test for patients with type 2 diabetes and chronic kidney disease.
  • The collaboration aims to identify patients at higher risk for progressive kidney function decline earlier, enabling more targeted therapeutic interventions and personalized care plans.
  • The test will be available to all MVP customers in New York, including Medicare and Medicaid beneficiaries, and is recommended by KDIGO clinical guidelines.
  • Renalytix reports measurable improvements in patient outcomes and quality metrics, including HEDIS measures for blood pressure and HbA1c control in high-risk populations where the test is implemented.

Fangzhou and Novo Nordisk Partner to Create AI-Powered Chronic Disease Management Ecosystem in China

AI
  • Fangzhou Inc., China's leading online chronic disease management platform serving 49.2 million registered users, has signed a Memorandum of Understanding with Novo Nordisk to collaborate on managing diabetes and obesity through AI-powered solutions.
  • The partnership will leverage Novo Nordisk's expertise in diabetes and obesity treatment combined with Fangzhou's smart healthcare ecosystem to create comprehensive health management services including medication guidance, efficacy tracking, and health education.
  • The collaboration aims to shift from a "disease-centered" to a "health-centered" model, providing patients with more convenient one-stop healthcare services while supporting China's "Healthy China 2030" strategic objectives.
  • Both companies plan to explore further innovative collaborations in the medical industry's digital transformation to benefit patients with serious chronic diseases through early screening, diagnosis, and treatment implementation.

One Biosciences Secures €15 Million Series A to Advance AI-Powered Single-Cell Cancer Diagnostics Platform

AI
  • One Biosciences raised €15 million in Series A financing led by Redmile Group and Blast to advance its OneMap platform for single-cell cancer diagnostics.
  • The AI-powered platform generates detailed functional profiles of patient tumors to guide treatment decisions and improve patient selection for clinical trials.
  • Funding will accelerate clinical development of OneMap and support strategic partnerships with pharmaceutical and biotech companies.
  • The company's total funding now exceeds €20 million, positioning OneMap as a clinical tool for precision oncology applications.

Fifty1 Labs Partners with BioSpark AI to Accelerate Drug Repurposing Through Advanced Literature Mining

AI
  • Fifty1 AI Labs announces strategic partnership with intent to acquire BioSpark AI Technologies, combining AI-powered literature mining with predictive modeling for drug repurposing applications.
  • The collaboration has successfully structured over 2,000 real-world treatment pathways from medical literature using BioSpark's patented AI system for clinical data extraction.
  • The partnership aims to transform functional medicine by automating the analysis of patient journeys and treatment outcomes from vast volumes of unstructured clinical data.
  • Next phase involves AI-guided hypothesis generation using proprietary models to identify dose-response trends and synergistic drug combinations for clinical validation.

Velocity Clinical Research Partners with Palantir to Automate Clinical Trial Payment Reconciliation Using AI

AI
  • Velocity Clinical Research has announced a strategic partnership with Palantir Technologies to automate the complex payments reconciliation process in clinical trials using advanced artificial intelligence.
  • The collaboration integrates Palantir's agentic AI technology with Velocity's proprietary workflows, successfully processing and reconciling customer payment report entries while saving significant time for finance teams.
  • The automated reconciliation solution transforms months of manual effort into near-instantaneous insights, allowing finance teams to focus on strategic, high-value work instead of administrative tasks.
  • This partnership represents a significant step toward modernizing clinical trial operations and unlocking efficiencies that will benefit sponsors, sites, and patients.

10x Genomics Partners with Singapore Institute to Launch AI-Driven Cancer Drug Discovery Study

AIDrug DiscoveryPrecision Medicine
  • 10x Genomics and A*STAR Genome Institute of Singapore announced the TISHUMAP project, an ambitious collaboration to analyze up to 2,500 clinical tissue samples using AI and spatial biology technology.
  • The study will focus on gastric, liver, and colorectal cancers, utilizing 10x Genomics' Xenium platform to visualize gene activity within individual cells in intact tissues.
  • The collaboration aims to accelerate drug target discovery and enable precision medicine by identifying novel biomarkers and therapeutic targets for cancer and inflammatory diseases.
  • Advanced AI will be combined with spatial omics data to detect critical patterns across large datasets, potentially leading to new diagnostics and personalized treatment plans.

OpenEvidence Raises $210 Million Series B to Expand AI-Powered Medical Research Platform for Physicians

AI
  • OpenEvidence, an AI-powered medical search engine for physicians, raised $210 million in Series B funding at a $3.5 billion valuation, co-led by Google Ventures and Kleiner Perkins.
  • The platform is used by over 40% of U.S. physicians daily and supports over 8.5 million clinical consultations per month, demonstrating over 2,000% year-over-year growth.
  • The company launched OpenEvidence DeepConsult, an AI agent that provides physicians with PhD-level medical research capabilities, analyzing hundreds of peer-reviewed studies in parallel.
  • Strategic partnerships with leading medical journals including JAMA and The New England Journal of Medicine enable instant access to evidence-based medical information for clinical decision-making.

MSBAI Secures $2M DoD Phase III Contract for GURU Generation 2 AI Platform

AI
  • MSBAI has been awarded a $2 million Phase III contract by the U.S. Department of Defense for GURU Generation 2, an AI-powered automation platform for engineering workflows.
  • The GURU platform reduces simulation failure rates from 88% to 2% and cuts setup times from hours or days to minutes for computational fluid dynamics simulations.
  • GURU Generation 2 will scale across key military supercomputers to support over 5,000 defense scientists and engineers in hypersonic vehicle development.
  • The contract elevates MSBAI to 'SBIR unicorn' status and positions the company for further DoD investments in AI-accelerated engineering innovation.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.